Hemogenyx Pharmaceuticals (LON:HEMO) Posts Quarterly Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) issued its quarterly earnings data on Thursday. The company reported GBX (170.60) EPS for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Stock Performance

Shares of HEMO opened at GBX 674 on Friday. Hemogenyx Pharmaceuticals has a 12-month low of GBX 124 and a 12-month high of GBX 1,800. The stock has a market cap of £43.30 million, a P/E ratio of -2.92 and a beta of 1.54. The company has a current ratio of 0.43, a quick ratio of 6.72 and a debt-to-equity ratio of -440.54. The company has a 50-day moving average of GBX 971.75 and a two-hundred day moving average of GBX 833.40.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.